Clinical data | |
---|---|
Trade names | Velsipity |
Other names | APD334, APD-334 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a623050 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Sphingosine-1-phosphate receptor modulator |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 97.9% |
Metabolism | Liver ( CYP2C8, 2C9, 3A4) |
Elimination half-life | 30 hours |
Excretion | Feces (82%), kidneys (5%) |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H26F3NO3 |
Molar mass | 457.493 g·mol−1 |
3D model ( JSmol) | |
| |
|
Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. [6] It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system. [6] It is taken by mouth. [6]
The most common side effects include lymphopenia (low levels of lymphocytes) and headache. [8]
Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer. [10] Etrasimod was approved for medical use in the United States in October 2023, [6] and in the European Union in February 2024. [8]
Etrasimod is used for the treatment of moderate to severe ulcerative colitis. [6] [8]
It works by causing T cells to become trapped in the lymph nodes, preventing them from entering the bloodstream, from where they would travel to other tissues in the body and mediate inflammation. [11] [12] [13] [14] [15] [16]
Velsipity was approved by the US Food and Drug Administration (FDA) in October 2023. [6] [17] [18]
In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Velsipity, intended for the treatment of ulcerative colitis. [8] The applicant for this medicinal product is Pfizer Europe MA EEIG. [8] Etrasimod was approved for medical use in the European Union in February 2024. [8]
Etrasimod is the international nonproprietary name. [19]
Clinical data | |
---|---|
Trade names | Velsipity |
Other names | APD334, APD-334 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a623050 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Sphingosine-1-phosphate receptor modulator |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 97.9% |
Metabolism | Liver ( CYP2C8, 2C9, 3A4) |
Elimination half-life | 30 hours |
Excretion | Feces (82%), kidneys (5%) |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H26F3NO3 |
Molar mass | 457.493 g·mol−1 |
3D model ( JSmol) | |
| |
|
Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. [6] It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system. [6] It is taken by mouth. [6]
The most common side effects include lymphopenia (low levels of lymphocytes) and headache. [8]
Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer. [10] Etrasimod was approved for medical use in the United States in October 2023, [6] and in the European Union in February 2024. [8]
Etrasimod is used for the treatment of moderate to severe ulcerative colitis. [6] [8]
It works by causing T cells to become trapped in the lymph nodes, preventing them from entering the bloodstream, from where they would travel to other tissues in the body and mediate inflammation. [11] [12] [13] [14] [15] [16]
Velsipity was approved by the US Food and Drug Administration (FDA) in October 2023. [6] [17] [18]
In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Velsipity, intended for the treatment of ulcerative colitis. [8] The applicant for this medicinal product is Pfizer Europe MA EEIG. [8] Etrasimod was approved for medical use in the European Union in February 2024. [8]
Etrasimod is the international nonproprietary name. [19]